Payment overview · 2025
General Payments
$368.20
16 reported records · 6 companies
Healthcare provider profile · identity verified
Alberto Rozo, D.O.
Allopathic & Osteopathic Physicians|Internal Medicine · JACKSON HEIGHTS, NY · NPI 1295796464
Verified facts
What the public records show
CMS Open Payments records show Alberto Rozo, D.O. received $368.20 in general payments during 2025 across 16 reported records.
Novo Nordisk Inc accounted for 67.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 8 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Ozempic, Rybelsus.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Prolia by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 353 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 56 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 595 claims for Jardiance by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNJARDY as an associated drug or biological on 33 records involving 33 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Synjardy by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 304 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 54 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 201 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $248.99 | 67.6% | 11 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $29.46 | 8.0% | 1 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $24.71 | 6.7% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $24.42 | 6.6% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $20.34 | 5.5% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $20.28 | 5.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $368.20 | 16 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $220.95 | 10 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $220.95 | 10 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $29.46 | 1 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $24.71 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $24.42 | 1 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $20.34 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $20.28 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $20.28 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 595 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 304 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 54 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
22 | 18 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
353 | 100 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
56 | 23 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
595 | 172 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | SYNJARDY open payments reported associated product |
CMS Open Payments — General Payments 33 supporting records · 33 recipient NPIs · example record 1222725005 |
Synjardy · 2024 Exact normalized brand match · 1 Part D row |
40 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
304 | 78 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
54 | 13 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
201 | 68 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 2263 | 840 |
| Metformin Hcl | Metformin Hcl | 1482 | 534 |
| Amlodipine Besylate | Amlodipine Besylate | 1425 | 496 |
| Levothyroxine Sodium | Levothyroxine Sodium | 1424 | 485 |
| Simvastatin | Simvastatin | 1257 | 425 |
| Lisinopril | Lisinopril | 1120 | 413 |
| Losartan Potassium | Losartan Potassium | 1073 | 378 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 874 | 356 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 766 | 265 |
| Omeprazole | Omeprazole | 749 | 289 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 683 | 279 |
| Metoprolol Succinate | Metoprolol Succinate | 677 | 235 |
| Jardiance | Empagliflozin | 595 | 172 |
| Meloxicam | Meloxicam | 525 | 231 |
| Alendronate Sodium | Alendronate Sodium | 513 | 210 |
| Naproxen | Naproxen | 497 | 263 |
| Vascepa | Icosapent Ethyl | 488 | 156 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 476 | 152 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 453 | 152 |
| Tamsulosin Hcl | Tamsulosin Hcl | 440 | 162 |
| Azithromycin | Azithromycin | 413 | 342 |
| Diclofenac Sodium | Diclofenac Sodium | 355 | 176 |
| Farxiga | Dapagliflozin Propanediol | 353 | 100 |
| Hydrochlorothiazide | Hydrochlorothiazide | 331 | 135 |
| Fluticasone Propionate | Fluticasone Propionate | 313 | 138 |
| Prednisone | Prednisone | 311 | 220 |
| Gabapentin | Gabapentin | 306 | 124 |
| Ozempic | Semaglutide | 304 | 78 |
| Januvia | Sitagliptin Phosphate | 303 | 80 |
| Azelastine Hcl | Azelastine Hcl | 300 | 127 |
| Montelukast Sodium | Montelukast Sodium | 300 | 117 |
| Pantoprazole Sodium | Pantoprazole Sodium | 271 | 102 |
| Carvedilol | Carvedilol | 244 | 87 |
| Zolpidem Tartrate | Zolpidem Tartrate | 237 | 51 |
| Promethazine Hcl | Promethazine Hcl | 233 | 191 |
| Glimepiride | Glimepiride | 223 | 73 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 206 | 98 |
| Eliquis | Apixaban | 201 | 68 |
| Meclizine Hcl | Meclizine Hcl | 199 | 95 |
| Pravastatin Sodium | Pravastatin Sodium | 178 | 67 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 171 | 64 |
| Clopidogrel | Clopidogrel Bisulfate | 169 | 61 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 168 | 42 |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 163 | 75 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 158 | 52 |
| Atenolol | Atenolol | 155 | 46 |
| Ammonium Lactate | Ammonium Lactate | 153 | 65 |
| Mometasone Furoate | Mometasone Furoate | 151 | 87 |
| Metoprolol Tartrate | Metoprolol Tartrate | 143 | 58 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 140 | 47 |
| Famotidine | Famotidine | 131 | 67 |
| Furosemide | Furosemide | 130 | 57 |
| Ibandronate Sodium | Ibandronate Sodium | 122 | 37 |
| Ezetimibe | Ezetimibe | 119 | 61 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 114 | 102 |
| Xarelto | Rivaroxaban | 112 | 32 |
| Baclofen | Baclofen | 106 | 54 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 106 | 40 |
| Metformin Hcl Er | Metformin Hcl | 105 | 33 |
| Donepezil Hcl | Donepezil Hcl | 104 | 43 |
| Finasteride | Finasteride | 102 | 37 |
| Ibuprofen | Ibuprofen | 102 | 75 |
| Ketoconazole | Ketoconazole | 96 | 47 |
| Valsartan | Valsartan | 96 | 38 |
| Easy Touch Alcohol Prep Pads | Alcohol Antiseptic Pads | 92 | 38 |
| Breo Ellipta | Fluticasone/Vilanterol | 87 | 27 |
| Fenofibrate | Fenofibrate,micronized | 85 | 30 |
| Allopurinol | Allopurinol | 84 | 31 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 83 | 30 |
| Dicyclomine Hcl | Dicyclomine Hcl | 79 | 51 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 79 | 28 |
| Linzess | Linaclotide | 78 | 30 |
| Fenofibrate | Fenofibrate | 76 | 32 |
| Sertraline Hcl | Sertraline Hcl | 76 | 33 |
| Alprazolam | Alprazolam | 75 | 19 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 73 | 57 |
| Tresiba Flextouch U-100 | Insulin Degludec | 73 | 25 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 72 | 31 |
| Labetalol Hcl | Labetalol Hcl | 71 | 23 |
| Doxycycline Hyclate | Doxycycline Hyclate | 68 | 53 |
| Fenofibrate | Fenofibrate Nanocrystallized | 68 | 20 |
| Valacyclovir | Valacyclovir Hcl | 68 | 43 |
| Single Use Swab | Alcohol Antiseptic Pads | 67 | 32 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 65 | 29 |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 64 | 34 |
| Ramipril | Ramipril | 64 | 21 |
| Celecoxib | Celecoxib | 63 | 50 |
| Hydrocortisone | Hydrocortisone | 62 | 40 |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 61 | 25 |
| Nifedipine Er | Nifedipine | 60 | 27 |
| Procto-Med Hc | Hydrocortisone | 57 | 22 |
| Enalapril Maleate | Enalapril Maleate | 56 | 21 |
| Symbicort | Budesonide/Formoterol Fumarate | 56 | 23 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 55 | 52 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 54 | 19 |
| Rybelsus | Semaglutide | 54 | 13 |
| Spironolactone | Spironolactone | 54 | 20 |
| Alcohol Swabs | Alcohol Antiseptic Pads | 51 | 25 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 51 | 19 |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 50 | 21 |
| Tradjenta | Linagliptin | 49 | 18 |
| Chlorthalidone | Chlorthalidone | 48 | 15 |
| Diclofenac Sodium Er | Diclofenac Sodium | 48 | 23 |
| Entresto | Sacubitril/Valsartan | 47 | 15 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 47 | 16 |
| Novolog Flexpen | Insulin Aspart | 47 | 14 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 46 | 43 |
| Memantine Hcl | Memantine Hcl | 45 | 18 |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 44 | 13 |
| Benazepril Hcl | Benazepril Hcl | 44 | 15 |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 42 | 13 |
| Hydralazine Hcl | Hydralazine Hcl | 42 | 13 |
| Proctozone-Hc | Hydrocortisone | 41 | 16 |
| Telmisartan | Telmisartan | 41 | 14 |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 41 | 16 |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 41 | 20 |
| Synjardy | Empagliflozin/Metformin Hcl | 40 | suppressed |
| Clonazepam | Clonazepam | 38 | suppressed |
| Latanoprost | Latanoprost | 37 | 12 |
| Mupirocin | Mupirocin | 37 | 26 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 36 | 19 |
| Fluconazole | Fluconazole | 35 | 30 |
| Synthroid | Levothyroxine Sodium | 35 | 16 |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 31 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 31 | 14 |
| Oxybutynin Chloride | Oxybutynin Chloride | 31 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 31 | suppressed |
| Trulicity | Dulaglutide | 30 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 29 | 11 |
| Glipizide | Glipizide | 28 | 11 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 28 | 15 |
| Restasis | Cyclosporine | 28 | suppressed |
| Alcohol Pads | Alcohol Antiseptic Pads | 27 | suppressed |
| Cephalexin | Cephalexin | 27 | 25 |
| Irbesartan | Irbesartan | 27 | 13 |
| Terconazole | Terconazole | 27 | 23 |
| Tizanidine Hcl | Tizanidine Hcl | 27 | 11 |
| Trazodone Hcl | Trazodone Hcl | 27 | 14 |
| Clotrimazole | Clotrimazole | 26 | 14 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 26 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 25 | suppressed |
| Trulance | Plecanatide | 25 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 24 | suppressed |
| Loperamide | Loperamide Hcl | 24 | 22 |
| Escitalopram Oxalate | Escitalopram Oxalate | 23 | suppressed |
| Folic Acid | Folic Acid | 23 | 11 |
| Acyclovir | Acyclovir | 22 | 13 |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 22 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 22 | 15 |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 22 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 22 | 13 |
| Paroxetine Hcl | Paroxetine Hcl | 22 | 14 |
| Prolia | Denosumab | 22 | 18 |
| Torsemide | Torsemide | 22 | suppressed |
| Calcitonin-Salmon | Calcitonin,salmon,synthetic | 21 | suppressed |
| Dymista | Azelastine/Fluticasone | 21 | suppressed |
| Lovastatin | Lovastatin | 21 | suppressed |
| Methylprednisolone | Methylprednisolone | 21 | 19 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 21 | 16 |
| Sucralfate | Sucralfate | 21 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 21 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 20 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 20 | suppressed |
| Glipizide Er | Glipizide | 20 | suppressed |
| Levetiracetam | Levetiracetam | 20 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 18 | 18 |
| Pro Comfort Alcohol Pads | Alcohol Antiseptic Pads | 18 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 18 | suppressed |
| Ciclopirox | Ciclopirox | 17 | 11 |
| Colchicine | Colchicine | 17 | suppressed |
| Lactulose | Lactulose | 17 | suppressed |
| Myrbetriq | Mirabegron | 17 | suppressed |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 17 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 17 | suppressed |
| Halobetasol Propionate | Halobetasol Propionate | 16 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 16 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 16 | suppressed |
| Tiadylt Er | Diltiazem Hcl | 16 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 16 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 15 | suppressed |
| Creon | Lipase/Protease/Amylase | 15 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 15 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 15 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 15 | suppressed |
| Lansoprazole | Lansoprazole | 15 | suppressed |
| Mounjaro | Tirzepatide | 15 | suppressed |
| Potassium Chloride | Potassium Chloride | 15 | suppressed |
| Repaglinide | Repaglinide | 15 | suppressed |
| Betamethasone Diprop Augmented | Betamethasone/Propylene Glyc | 14 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 14 | 11 |
| Dilt-Xr | Diltiazem Hcl | 14 | suppressed |
| Omeprazole-Sodium Bicarbonate | Omeprazole/Sodium Bicarbonate | 14 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 14 | suppressed |
| Anastrozole | Anastrozole | 13 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 13 | suppressed |
| Dorzolamide Hcl | Dorzolamide Hcl | 13 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 13 | suppressed |
| Felodipine Er | Felodipine | 13 | suppressed |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 13 | suppressed |
| Lorazepam | Lorazepam | 13 | suppressed |
| Olmesartan-Amlodipine-Hctz | Olmesartan/Amlodipin/Hcthiazid | 13 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 13 | 12 |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 13 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Alcohol Swab | Alcohol Antiseptic Pads | 12 | suppressed |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 12 | suppressed |
| Cilostazol | Cilostazol | 12 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 12 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 12 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 12 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 12 | suppressed |
| Fluocinolone Acetonide Oil | Fluocinolone Acetonide Oil | 12 | suppressed |
| Levemir Flexpen | Insulin Detemir | 12 | suppressed |
| Nitroglycerin | Nitroglycerin | 12 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 12 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 11 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 11 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 11 | suppressed |
| Fluocinonide | Fluocinonide | 11 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 11 | suppressed |
| Jentadueto | Linagliptin/Metformin Hcl | 11 | suppressed |
| Levalbuterol Tartrate Hfa | Levalbuterol Tartrate | 11 | suppressed |
| Lidocaine Hcl Viscous | Lidocaine Hcl | 11 | 11 |
| Metoprolol-Hydrochlorothiazide | Metoprolol/Hydrochlorothiazide | 11 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 11 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 11 | suppressed |
| Semglee (Yfgn) Pen | Insulin Glargine-Yfgn | 11 | suppressed |
| True Comfort Pro Alcohol Pads | Alcohol Antiseptic Pads | 11 | suppressed |
| Ubrelvy | Ubrogepant | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $368.20 · 16 records | Novo Nordisk Inc | AIRSUPRA, IBSRELA, JARDIANCE, OTEZLA, Ozempic, PAXLOVID, REPATHA, Rybelsus | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Amgen Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error